Immunotherapy startup moves into the University of Maryland BioPark - Technical.ly Baltimore

Sciences

Sep. 6, 2018 12:53 pm

Immunotherapy startup moves into the University of Maryland BioPark

ImmuCision BioTherapeutics made the move after securing funding and validation for its work with dendritic cells – all this year.

The University of Maryland BioPark.

(Courtesy photo)

After a pair of key milestones this year, a startup working on a new way to treat cancer is opening an office in Baltimore city.

ImmuCision BioTherapeutics is taking office and lab space in the space at the University of Maryland BioPark at 801 Baltimore St.

The startup’s technology was invented by Hua Cheng, who is faculty member at the university. It’s taking a new approach in the fledgling area of immunotherapy, which harnesses that body’s own immune system to treat cancer.

ICBT’s work is focused on dendritic cells, which Cheng described as a “regulator” of the immune system. The founder sees the cells as a potential catalyst to create immune cells that could be used to treat types of cancer that are not addressed by chemotherapy or other existing treatments.

“ImmuCision has developed an innovative method that can significantly improve the growth (and quality) of dendritic cells in the lab,” Cheng said in a statement. “In addition, the newly developed method allows efficient genetic modification to enhance dendritic cell function.”

It’s the latest in a year that’s brought a flurry of activity for the company. Launched in 2017, the startup secured a licensing deal with UMB through UM Ventures. Earlier this year, it received $2 million as part of a sublicensing deal with a pharmaceutical firm in China. ICBT declined to disclose the name. In May, a study published in Proceedings of the National Academy of Sciences showed promising results in animal models. In terms of IP, an application is out for an international patent.

The trajectory has the attention of university tech transfer leaders.

“With ImmuCision, the BioPark has added another important healthcare startup to its innovative tenant base,” UM Ventures Director Jim Hughes said in a statement. “We are excited that the company has received validation through a peer-reviewed publication and an external investment.”

ICBT is one of a half-dozen therapeutics companies currently operating in the biomedical research park on the west side of Martin Luther King, Jr. Blvd. Earlier this year, biotech manufacturing firm Paragon Bioservices also announced plans to expand its existing space within the same building. The latest expansions come after a pair of departures by firms who moved to the counties in 2017. By the end of last year, the BioPark also expanded with the opening of the GRID innovation hub at the nearby Lion Brothers Building.

Advertisement

-30-
JOIN THE COMMUNITY, BECOME A MEMBER
Already a member? Sign in here

Advertisement

Gliknik receives $15M payment from Pfizer after reaching clinical milestone

Tsao Baltimore dives into local history with second line of watches

MindX, a startup developing brain-controlled smartglasses, names Julia Brown as CEO

SPONSORED

Baltimore

Pitch to speak at Comcast Labs Connect’s data security conference

Baltimore

StraighterLine

Director of Product Management (Programs)

Apply Now
Baltimore, MD

SmartLogic

Product Designer

Apply Now
Baltimore, MD 21201

Agora Financial

Jr. Project Manager / Business Analyst

Apply Now

Morgan State joins blockchain partnership with Silicon Valley-based Ripple

Processing Community Day connects art and tech

Have a look at WeWork’s first space in Maryland

SPONSORED

Baltimore

Arrive ready to grow at 14 West

Canton in Baltimore, MD

iVeia

Software Engineer (Embedded/SoC)

Apply Now
Baltimore, MD

SmartLogic

Developer

Apply Now
Baltimore, MD 21201

The Oxford Club

Web Developer

Apply Now

Sign-up for daily news updates from Technical.ly Baltimore

Do NOT follow this link or you will be banned from the site!